INVESTOR ALERT: Investigation of Corcept Therapeutics Incorporated (CORT) by Holzer & Holzer, LLC

Core Insights - Holzer & Holzer, LLC is investigating whether Corcept Therapeutics Incorporated complied with federal securities laws following the issuance of a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for relacorilant [1] - The announcement led to a decline in Corcept's stock price, indicating potential investor concerns about the company's regulatory challenges [1] Company Overview - Corcept Therapeutics is focused on developing treatments for patients with conditions related to hypercortisolism, specifically hypertension [1] - The company is publicly traded on NASDAQ under the ticker symbol CORT [1] Legal Context - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in securities litigation, including class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]